Please assess the completion status of the following clinical trial:

Trial Title: Stem Cell Transplant, Chemotherapy, and Biological Therapy in Treating Patients With High-Risk or Refractory Multiple Myeloma

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE1/PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of myeloma meeting 1 of the following criteria:~  * Myeloma has relapsed, progressed, or failed to respond after at least one prior course of therapy (consisting of at least 2 treatment cycles or months of therapy)~    * Failure to respond would correspond to a reduction of less than or equal to 25% of the original, diagnostic serum or urine paraprotein measurement~ * Myeloma has responded partially to initial therapy but a complete response (immunofixation negative) has NOT developed after a minimum of 3 cycles or months of initial therapy~ * Myeloma has high-risk features as defined by the presence of one or more cytogenetic abnormalities known to confer a poor outcome even after standard autotransplants (e.g., complex karyotype \[≥ 3 abnormalities\], t(4;14), t(14;16), del (17) (p13.1), and/or chromosome 13 abnormalities)~    * May be enrolled even while in complete or near-complete remission~   * Extended disease-free survival after autotransplantation would be unexpected for these patients and therefore especially meaningful~* Must have measurable disease~  * Measurable disease may include quantifiable or detectable levels of serum or urine paraprotein~    * For patients with minimally secretory disease or non-secretory myeloma on study entry, serum free λ or κ light chain levels may be measured and used for disease monitoring if abnormal~   * Patients who are in complete remission at the time of proposed study entry (serum and urine immunofixation consistently negative) are not eligible unless their disease meets the criteria for high-risk disease~* No known history of myelodysplasia~PATIENT CHARACTERISTICS:~Inclusion criteria:~* ECOG performance status 0-2 (unless due solely to bone pain)~* Creatinine ≤ 3.0 mg/dL and not on dialysis~* WBC ≥ 3,000/mm³~* Platelet count ≥ 100,000/mm³~* AST ≤ 2 times upper limit of normal~* Bilirubin ≤ 2.0 mg/dL (unless due to Gilbert's syndrome)~* LVEF ≥ 45%~  * A lower LVEF is permissible if a formal cardiologic evaluation reveals no evidence for clinically significant functional impairment~* FEV1, FVC, TLC, and DLCO ≥ 40% predicted~  * Patients who are unable to complete pulmonary function tests due to bone pain or fracture must have a high-resolution CT scan of the chest and must have acceptable arterial blood gases (room air PO_2 \> 70 mmHg)~* Women of child-bearing potential and their spouses or partners must be willing to use adequate contraception for the duration of the active treatment phase of the study~  * Contraceptive measures must be continued as long as the patient remains on maintenance thalidomide in accordance with the STEPS program~Exclusion criteria~* Pregnant or nursing~* HIV, HTLV-1/2 seropositivity~* Known history of chronic active hepatitis or liver cirrhosis (if suspected by laboratory studies, should be confirmed by liver biopsy)~* Active hepatitis B (as defined by positive hepatitis B surface antigen)~  * Positive hepatitis C virus (HCV) antibody is NOT an exclusion~* History of severe autoimmune disease requiring steroids or other immunosuppressive treatments~* Active immune-mediated diseases including:~  * Connective tissue diseases~ * Uveitis~ * Sarcoidosis~ * Inflammatory bowel disease~ * Multiple sclerosis~* Evidence or history of other significant cardiac, hepatic, renal, ophthalmologic, psychiatric, or gastrointestinal disease that might increase the risks of participating in the study~* Active bacterial, viral or fungal infections.~PRIOR CONCURRENT THERAPY:~Inclusion criteria~* Recovered from any toxicities related to prior therapy or at least returned to their baseline level of organ function~* Patients should be off of glucocorticoids for at least 2 weeks and/or thalidomide therapy for at least 1 week prior to enrollment~* At least 2 weeks since prior steroid therapy or chemotherapy~Exclusion criteria~* Prior autotransplant or allogeneic transplant~* More than 4 distinct, prior courses of therapy for myeloma~* Also see Disease Characteristics

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Group 1 (HLA-A2 positive) (Type: EXPERIMENTAL): Patients receive the following peptides emulsified in incomplete Freund's adjuvant VG: I) hTERT I540 peptide; ii) hTERT R572Y peptide; iii) hTERT D988Y peptide; iv) survivin Sur1M2 peptide ; and v) CMV control peptide N495 subcutaneously (SC). Patients also receive sargramostim (GM-CSF) SC and pneumococcal conjugate vaccine intramuscularly.
- Group 2 (Type: EXPERIMENTAL): Patients receive pneumococcal conjugate vaccine intramuscularly and GM-CSF subcutaneously.
- Second group 1 (Type: EXPERIMENTAL): On days 14, 42, and 90 post-transplant, patients receive peptides and GM-CSF subcutaneously and pneumococcal conjugate vaccine intramuscularly.
- Second group 2 (Type: EXPERIMENTAL): On day 14, 42, 90 post-transplant, patients receive pneumococcal conjugate vaccine intramuscularly and GM-CSF subcutaneously.

Based on this trial design, predict the completion outcome and termination type (if applicable).